ATE493146T1 - Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren - Google Patents
Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retrovirenInfo
- Publication number
- ATE493146T1 ATE493146T1 AT02755576T AT02755576T ATE493146T1 AT E493146 T1 ATE493146 T1 AT E493146T1 AT 02755576 T AT02755576 T AT 02755576T AT 02755576 T AT02755576 T AT 02755576T AT E493146 T1 ATE493146 T1 AT E493146T1
- Authority
- AT
- Austria
- Prior art keywords
- igf
- cats
- vaccine
- aid
- particularly against
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 5
- 241000282324 Felis Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241000282326 Felis catus Species 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 229940031567 attenuated vaccine Drugs 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 229940031551 inactivated vaccine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
- 229940031626 subunit vaccine Drugs 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0111736A FR2829498B1 (fr) | 2001-09-11 | 2001-09-11 | Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins |
| PCT/IB2002/003638 WO2003022886A1 (en) | 2001-09-11 | 2002-09-10 | Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE493146T1 true ATE493146T1 (de) | 2011-01-15 |
Family
ID=8867163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02755576T ATE493146T1 (de) | 2001-09-11 | 2002-09-10 | Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1425305B1 (de) |
| JP (1) | JP2005516587A (de) |
| AT (1) | ATE493146T1 (de) |
| CA (1) | CA2459769C (de) |
| DE (1) | DE60238773D1 (de) |
| FR (1) | FR2829498B1 (de) |
| WO (1) | WO2003022886A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| JP2007522801A (ja) | 2004-01-07 | 2007-08-16 | リーブテック，インコーポレイテッド | 一体のスパージャーとセンサー受け器を有する混合用袋 |
| CA2629522A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US8603808B2 (en) | 2008-05-08 | 2013-12-10 | Merial Limited | Leishmania vaccine using sand fly salivary immunogen |
| BR112014001287B1 (pt) | 2011-07-20 | 2020-12-08 | Centre National De La Recherche Scientifique | vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina |
| ES2711878T3 (es) | 2012-03-20 | 2019-05-08 | Merial Inc | Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma |
| CN111848785B (zh) * | 2020-07-10 | 2022-09-06 | 青岛博隆基因工程有限公司 | 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986000619A1 (en) * | 1984-07-13 | 1986-01-30 | Chiron Corporation | Prepro insulin-like growth factors i and ii |
| US4963665A (en) * | 1986-01-07 | 1990-10-16 | Washington University | Human preproinsulin-like growth factor I |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| AU4238493A (en) * | 1992-05-08 | 1993-12-13 | Thomas Jefferson University | IGF-1 analogs |
| AU1439095A (en) * | 1993-12-15 | 1995-07-03 | Thomas Jefferson University | Igf-1 analogs |
| GB9605124D0 (en) * | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
| FR2751223B1 (fr) * | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
| WO1998024922A1 (en) * | 1996-12-02 | 1998-06-11 | Valentis, Inc. | Insulin-like growth factor i (igf-i) expression system and methods of use |
| GB9926968D0 (en) * | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
-
2001
- 2001-09-11 FR FR0111736A patent/FR2829498B1/fr not_active Expired - Lifetime
-
2002
- 2002-09-10 JP JP2003526958A patent/JP2005516587A/ja active Pending
- 2002-09-10 EP EP02755576A patent/EP1425305B1/de not_active Expired - Lifetime
- 2002-09-10 CA CA2459769A patent/CA2459769C/en not_active Expired - Lifetime
- 2002-09-10 AT AT02755576T patent/ATE493146T1/de not_active IP Right Cessation
- 2002-09-10 DE DE60238773T patent/DE60238773D1/de not_active Expired - Lifetime
- 2002-09-10 WO PCT/IB2002/003638 patent/WO2003022886A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1425305B1 (de) | 2010-12-29 |
| CA2459769C (en) | 2013-05-28 |
| WO2003022886A1 (en) | 2003-03-20 |
| EP1425305A1 (de) | 2004-06-09 |
| JP2005516587A (ja) | 2005-06-09 |
| FR2829498B1 (fr) | 2003-11-28 |
| FR2829498A1 (fr) | 2003-03-14 |
| CA2459769A1 (en) | 2003-03-20 |
| DE60238773D1 (de) | 2011-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110359T1 (el) | Εμβολια με βαση σιρκοϊους χοιρων | |
| DK0956360T3 (da) | Poxvirusbaserede ekspressionsvektorer indeholdende heterologe inserts afledt af lentvirus | |
| EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
| EA200901060A1 (ru) | Новый способ и композиции | |
| WO2003048184A3 (en) | Flavivirus ns1 subunit vaccine | |
| BR0206823A (pt) | Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo | |
| WO2008151633A3 (en) | Vectors for vaccines against lentivirus infections | |
| WO2005081716A3 (en) | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) | |
| ATE461710T1 (de) | Nipah-virus-impfstoffe | |
| DE60238773D1 (de) | Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren | |
| DE602004018975D1 (de) | Promotoren zur expression im modifizierten vacciniavirus ankara | |
| MX2022000551A (es) | Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica. | |
| WO2023004407A3 (en) | Adeno-associated virus compositions and methods of use thereof | |
| ATE294857T1 (de) | Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze | |
| BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
| BR9713540A (pt) | Procedimento para a expressão do gene do vìrus da dengue | |
| ATE335507T1 (de) | Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze | |
| ATE473013T1 (de) | Induzierte immunantwort gegen den katzen- immunschwäche-virus | |
| FR2809960B1 (fr) | Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante | |
| ES2105984B1 (es) | Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas. | |
| BRPI0604365A (pt) | polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos | |
| WO2022090484A3 (en) | Viral vector | |
| Deryabin et al. | Obtaining classical swine fever virus E2 recombinant protein and DNA-vaccine on the basis of one subunit | |
| ATE547530T1 (de) | Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |